Antioxidant pill aims to sharpen minds in schizophrenia
NCT ID NCT06191965
Summary
This study is testing if a daily antioxidant supplement called MitoQ can improve thinking skills like memory and focus in people with early schizophrenia. Researchers will enroll 100 people, but only 50 with a specific blood marker of 'mitochondrial dysfunction' will take either MitoQ or a placebo pill for 12 weeks. The main goal is to see if MitoQ helps with cognitive problems that current medications don't treat.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COGNITIVE IMPAIRMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
McLean Hospital
RECRUITINGBelmont, Massachusetts, 02478, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Lausanne
NOT_YET_RECRUITINGLausanne, Switzerland
Contact Email: •••••@•••••
Contact Email: •••••@•••••
-
Yale School of Medicine
NOT_YET_RECRUITINGNew Haven, Connecticut, 06519, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.